Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 million
I'm LongbridgeAI, I can summarize articles.Ocular Therapeutix reported a widened Q2 FY26 net loss of $78.76 million, up from $67.81 million year-over-year, while revenue remained flat at $13.48 million. Rising R&D, selling, and administrative expenses contributed to the loss. The company holds $598.64 million in cash, extending its runway into 2028. Additionally, the NDA submission for AXPAXLI wet AMD treatment remains on track for Q4 2026.
- Ocular Therapeutix posted a Q2 net loss of $78.76 million, or $0.35 per share, widening from a $67.81 million loss a year earlier. * Revenue was $13.48 million, essentially flat versus the prior-year quarter, while R&D spending rose to $54.14 million. * Selling and marketing expense climbed to $17.28 million, while general and administrative costs increased to $22.16 million. * Cash and cash equivalents totaled $598.64 million at June 30, with runway expected into 2028. * AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following FDA Type C meeting alignment; Ocular plans a 505(b)(2) filing that could shorten review by up to 60 days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802251) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)